RxSight, Inc.
For the period ended Mar 31, 2025. Filed May 7, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2025 · Filed May 7, 2025
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Equity
CONDENSED CONSOLIDATED STATEMENTS OFSTOCKHOLDERS’ EQUITY
(In thousands, except number of shares)
| Common stock · Additional paid-in · Accumulated other · Accumulated · Total stockholders' | ||||||
|---|---|---|---|---|---|---|
| Shares | Amount | capital | comprehensive income | deficit | equity | |
| Balance at December 31, 2024 | 40,428,220 | $40 | $903,127 | $166 | $(622,095) | $281,238 |
| Shares issued for the exercise of stock options and vesting of restricted stock units | 210,332 | 1 | 696 | — | — | 697 |
| Shares redeemed for employee tax withholdings | (50,012) | — | (1,418) | — | — | (1,418) |
| Stock-based compensation expense | — | — | 7,140 | — | — | 7,140 |
| Unrealized loss on short-term investments and cash equivalents, net of tax | — | — | — | (157) | — | (157) |
| Foreign currency translation adjustment | — | — | — | 6 | — | 6 |
| Net loss | — | — | — | — | (8,190) | (8,190) |
| Balance at March 31, 2025 | 40,588,540 | $41 | $909,545 | $15 | $(630,285) | $279,316 |
See accompanying notes to unaudited condensed consolidated financial statements
CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY
(In thousands, except number of shares)
| Common stock · Additional paid-in · Accumulated other · Accumulated · Total stockholders' | |||||||
|---|---|---|---|---|---|---|---|
| Shares · Amount · capital · comprehensive loss · deficit · equity | |||||||
| Balance at December 31, 2023 | 36,139,513 | $36 | $754,971 | $(5) | $(594,640) | $160,362 | |
| Shares issued for the exercise of stock options and vesting of restricted stock units | 1,061,336 | 1 | 10,152 | — | — | 10,153 | |
| Shares redeemed for employee tax withholdings | (39,096) | — | (2,134) | — | — | (2,134) | |
| Stock-based compensation expense | — | — | 4,696 | — | — | 4,696 | |
| Unrealized loss on short-term investments and cash equivalents, net of tax | (45) | (45) | |||||
| Foreign currency translation adjustment | — | — | — | (3) | — | (3) | |
| Net loss | — | — | — | — | (9,100) | (9,100) | |
| Balance at March 31, 2024 | 37,161,753 | $37 | $767,685 | $(53) | $(603,740) | $163,929 | |
See accompanying notes to unaudited condensed consolidated financial statements
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.